Tier 1 — highest

Efficacy and acceptability of adjunctive n-acetylcysteine for psychotic disorders: Systematic review and meta-analysis

Qun Zhang, Ziping Liu, Ting Wang, Min Yu, Xiaoqian Li
Hum Psychopharmacol 2023 39(2):e2880

Bibliography

PubMed
PMID 37712506
DOI
10.1002/hup.2880
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignSystematic review and meta-analysis
ModelHuman
Sample8 randomized trials; 594 patients
InterventionAdjunctive NAC versus placebo/control
DurationVaried
EndpointsPANSS total; Positive symptoms; Negative symptoms; Adverse events

What the study showed, in plain terms

Pooled evaluation of NAC as an adjunct in schizophrenia-spectrum and related psychotic disorders.

Key findings

The meta-analysis did not demonstrate a consistent clinically meaningful improvement across core psychosis outcomes sufficient to support routine use.

What this study can and cannot tell us

Heterogeneous trials, background medications and durations; some individual domains may differ.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology